Ward J B, Henderson R E
Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston 77555-1110, USA.
Environ Health Perspect. 1996 Oct;104 Suppl 5(Suppl 5):895-900. doi: 10.1289/ehp.96104s5895.
Interest in the use of biological markers to evaluate future disease risk has increased greatly in recent years. Biomarkers are observable end points in a continuum of events leading from exposure to toxic agents to diseases that ultimately result from exposure. Because many significant diseases develop over long periods of time, methods for detecting early events that can predict risk are important for disease prevention. Biomarkers are generally categorized as detecting exposure, effects of exposure, or individual susceptibility to exposure. Although there has been significant progress in the technical development of biomarkers, implementation of their use in human populations has progressed much more slowly. We discuss four major needs in the development of biomarkers. First, new biomarkers need to be developed to fill gaps in our ability to observe steps in the continuum from exposure to disease. Second, the relationships between biomarker responses and disease pathology needs to be better understood. Third, the sensitivity, specificity, and variability of biomarkers need to be better characterized and they must be better validated as predictors of disease risk. Fourth, there are several societal impediments to the practical implementation of biomarker studies as public health tools. A common agreement among employers, employees, regulators, and the legal community must be established regarding appropriate and ethical uses and interpretation of biomarker data.
近年来,对使用生物标志物评估未来疾病风险的兴趣大幅增加。生物标志物是一系列事件中的可观察终点,这些事件从接触有毒物质开始,直至最终因接触而导致疾病。由于许多重大疾病的发展历时较长,因此检测能够预测风险的早期事件的方法对于疾病预防至关重要。生物标志物通常分为检测接触、接触效应或个体对接触的易感性。尽管生物标志物的技术开发取得了重大进展,但其在人群中的应用进展要缓慢得多。我们讨论了生物标志物开发中的四个主要需求。第一,需要开发新的生物标志物,以填补我们在观察从接触到疾病的连续过程中各步骤的能力方面的空白。第二,需要更好地理解生物标志物反应与疾病病理学之间的关系。第三,需要更好地表征生物标志物的敏感性、特异性和变异性,并且必须更好地验证它们作为疾病风险预测指标的有效性。第四,将生物标志物研究实际用作公共卫生工具存在若干社会障碍。雇主、雇员、监管机构和法律界必须就生物标志物数据的适当和道德使用及解释达成共识。